A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors (NCT06846671)
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Who can join: Review the eligibility criteria below.
Location: St Bernards Medical Center — Jonesboro, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (130 Sites)
Showing the first 25 of 130 sites.
- St Bernards Medical Center — Jonesboro, Arkansas
- UCLA Department of Medicine Hematologyoncology — Los Angeles, California
- Pih Health Whittier Hospital — Whittier, California
- Rocky Mountain Cancer Centers (Williams) Usor — Aurora, Colorado
- Florida Oncology and Hematology — Fort Myers, Florida
- Baptist Md Anderson Cancer Center — Jacksonville, Florida
- Cleveland Clinic Florida — Weston, Florida
- Emory University Winship Cancer Institute — Atlanta, Georgia
- Northside Cancer Center — Atlanta, Georgia
- Our Lady of the Lake Hospital — Baton Rouge, Louisiana
- American Oncology Partners of Maryland Pa — Bethesda, Maryland
- Corewell Health the Michigan Cancer Consortium — Grand Rapids, Michigan
- St Lukes Center For Cancer Care — Chesterfield, Missouri
- Oncology Hematology Associates — Springfield, Missouri
- St Vincent Frontier Cancer Center — Billings, Montana
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists — Omaha, Nebraska
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
- New York Cancer and Blood Specialists — Shirley, New York
- Optum Medical Care, Pc — Westbury, New York
- University Hospitals — Cleveland, Ohio
- Dayton Physician Network — Dayton, Ohio
- Oncology Associates of Oregon Willamette Valley Cancer Center — Eugene, Oregon
- West Penn Hospital — Pittsburgh, Pennsylvania
- Cancer Care Associates of York — York, Pennsylvania
- Baylor Scott and White Health — Temple, Texas
📞 Contact the Study Coordinator
Phone: (877) 828-5568
Email: clinicaltrials@beonemed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in CLL
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL — New Haven, Connecticut
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Anchorage, Alaska
Explore by condition: All CLL clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.